Cannabinoids drug interactions with anticoagulants and antiplatelets | ||
Drug | Effect | Intervention |
Warfarin | THC and CBD can cause competitive inhibition of CYP2C9 and inhibit metabolism of the S-warfarin isomer, leading to supratherapeutic international normalized ratio levels. |
|
DOACs (direct-acting oral anticoagulants) | CBD and possibly THC can increase DOACs level due to competitive inhibition of P-glycoproteins, and to a lesser extent CYP3A4. |
|
Clopidogrel | CBD and possibly THC can increase clopidogrel level due to the competitive inhibition of CYP2C19. |
|
Heparin/fondaparinux | No known interactions as these agents are processed by endothelial and renal cells and not metabolized by CYP enzymes, UGT, or P-glycoprotein. | |
Platelets | Immune thrombocytopenia with synthetic cannabis. |
|
CBD, cannabidiol; THC, tetrahydrocannabinol.